TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
← catalyst calendarNCT05548127 · readout in 12 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With Arvinas Estrogen Receptor, Inc..
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
37actual
Sites
39
Countries
Canada, Italy, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-23 | actual | When the study began enrolling |
| Primary completion | 2026-09-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-01 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Interventions
- Drug: ARV-471 — also filed as vepdegestrant, PF-07850327
- Drug: Abemaciclib
Primary outcomes
what the primary-completion date above is the date OFPhase 1b: number of participants with dose limiting toxicities
measured 28 days
Phase 2: percentage of participants with objective response by investigator assessment
measured Up to approximately 1 year
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed